Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228247 · ClinicalTrials.gov registry record · Phase 1
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
A Phase 1 study of Solid Tumors, Adult, sponsored by Hutchmed.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
- 11
- Study locations
NCT07228247: Recruiting Phase 1 study of Solid Tumors, Adult, sponsored by Hutchmed.
NCT07228247 is a Phase 1 study of Solid Tumors, Adult that is actively recruiting participants, run by Hutchmed. The registered enrollment target is 147 participants, below the 231-participant average among 5 other Solid Tumors, Adult trials with a reported enrollment target (36% lower). The trial reports 11 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07228247, a Phase 1 study of Solid Tumors, Adult, is actively recruiting participants, sponsored by Hutchmed.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
Primary Outcome
At least three participants will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN) will be used to guide dose escalation and to determine the MTD of HMPL-A251
Conditions Studied
Interventions
- DRUG HMPL-A251
Study Locations (11)
Other
- Peking University First Hospital - Beijing
- Hunan Cancer Hospital - Changsha
- Fujian Cancer Hospital - Fujian
- Sun Yat-sen University Cancer Center - Guangzhou
- The First Affiliated Hospital of Anhui Medical University - Hefei
- Henan Cancer Hospital - Zhengzhou
Colorado
- SCRI HealthONE - Denver
Florida
- BRCR Global - Plantation
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT07228247 shows while recruiting
NCT07228247 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 231-participant average among 5 other Solid Tumors, Adult trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Solid Tumors, Adult appearing as the primary indexed condition, and to 1 intervention - of which HMPL-A251 is the first listed.
NCT07228247 lists 11 locations in 6 states (Other, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT07228247 about?
NCT07228247 is a clinical study titled "A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors". This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
What is the current status of trial NCT07228247?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2025-12-16. Estimated completion is 2028-12-31.
What conditions does trial NCT07228247 study?
This clinical trial studies the following conditions: Solid Tumors, Adult.
What interventions are being tested in trial NCT07228247?
The interventions under investigation include: HMPL-A251 (DRUG).
Who is sponsoring clinical trial NCT07228247?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228247 being conducted?
This trial has 11 study locations across Colorado, Florida, New York, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
RECRUITING · Phase 1
-
Imaging of Solid Tumors Using FAP-2286
RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
RECRUITING · Phase 1
-
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI